GGrantIndex
← Leaderboards

William H Robinson

Stanford University

$16,848,609
Attributed
$22,063,878
Total exposure
21
Grants
19
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY200725
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$22,063,878 · 14
VA$0 · 7

By mechanism

R01$9,570,663 · 5
U19$3,552,920 · 2
T32$2,993,377 · 1
UH2$2,602,118 · 1
R33$1,198,929 · 1
RC1$1,000,000 · 1

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Success

Research focus

SuccessPathogenesisResponseTissuesAntibodiesLeadMediatingPreventInflammatoryCellsJointsNovel Therapeutic InterventionSamplingRheumatoid ArthritisAffectB-LymphocytesPlayProductionBloodCytokinePathway InteractionsAntigensBaseGenes

Grant awards (91)

Investigating Mucosal Breaks in the Initiation and Progression of Rheumatoid Arthritis$581,707
R01 · FY2025 · AR · contact PI
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis$570,031
R01 · FY2025 · AI · contact PI
Training Program in Adult and Pediatric Rheumatology$331,817
T32 · FY2025 · AR
BCCMA: Targeting Osteoarthritis Pain and Progression: Proteomics, RNASeq & Immunostaining to elucidate the immune pathotypes of OA$0
I01 · FY2025 · VA · contact PI
Investigating Mucosal Breaks in the Initiation and Progression of Rheumatoid Arthritis$593,790
R01 · FY2024 · AR · contact PI
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis$586,186
R01 · FY2024 · AI · contact PI
Training Program in Adult and Pediatric Rheumatology$363,366
T32 · FY2024 · AR
BCCMA: Targeting Osteoarthritis Pain and Progression: Proteomics, RNASeq & Immunostaining to elucidate the immune pathotypes of OA$0
I01 · FY2024 · VA · contact PI
Investigating Mucosal Breaks in the Initiation and Progression of Rheumatoid Arthritis$624,190
R01 · FY2023 · AR · contact PI
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis$587,726
R01 · FY2023 · AI · contact PI
Training Program in Adult and Pediatric Rheumatology$242,915
T32 · FY2023 · AR
Investigating the IL-4/13 Axis in Osteoarthritis$0
I01 · FY2023 · VA · contact PI
Targeting Mast Cells in Post-Traumatic Joint Rehabilitation and Osteoarthritis$0
I01 · FY2023 · VA · contact PI
BCCMA: Targeting Osteoarthritis Pain and Progression: Proteomics, RNASeq & Immunostaining to elucidate the immune pathotypes of OA$0
I01 · FY2023 · VA · contact PI
Investigating Mucosal Breaks in the Initiation and Progression of Rheumatoid Arthritis$629,632
R01 · FY2022 · AR · contact PI
Training Program in Adult and Pediatric Rheumatology$360,980
T32 · FY2022 · AR
Investigating the IL-4/13 Axis in Osteoarthritis$0
I01 · FY2022 · VA · contact PI
Targeting Mast Cells in Post-Traumatic Joint Rehabilitation and Osteoarthritis$0
I01 · FY2022 · VA · contact PI
Investigating Mucosal Breaks in the Initiation and Progression of Rheumatoid Arthritis$661,782
R01 · FY2021 · AR · contact PI
Training Program in Adult and Pediatric Rheumatology$310,849
T32 · FY2021 · AR
Investigating the IL-4/13 Axis in Osteoarthritis$0
I01 · FY2021 · VA · contact PI
Targeting Mast Cells in Post-Traumatic Joint Rehabilitation and Osteoarthritis$0
I01 · FY2021 · VA · contact PI
Training Program in Adult and Pediatric Rheumatology$322,405
T32 · FY2020 · AR
Stanford Technology Accelerating Medicines Partnership Center$25,001
UH2 · FY2020 · AR · contact PI
Investigating the IL-4/13 Axis in Osteoarthritis$0
I01 · FY2020 · VA · contact PI
Training Program in Adult and Pediatric Rheumatology$264,650
T32 · FY2019 · AR
Stanford Technology Accelerating Medicines Partnership Center$1
UH2 · FY2019 · AR · contact PI
Targeting Mast Cells in Post-Traumatic Joint Rehabilitation and Osteoarthritis$0
I01 · FY2019 · VA · contact PI
ShEEP Request for BioPlex 3D System$0
IS1 · FY2019 · VA · contact PI
Targeting Mast Cells in Post-Traumatic Joint Rehabilitation and Osteoarthritis$0
I01 · FY2019 · VA · contact PI
Large-Scale Sequencing and Characterizing of Autoantibody Responses$359,079
U19 · FY2018 · AI · contact PI
Genetic and Environmental Factors in the Response to Influenza Vaccination$312,144
U19 · FY2018 · AI · contact PI
Training Program in Adult and Pediatric Rheumatology$266,948
T32 · FY2018 · AR
FOCIS 2014 - 2018: The 14th through 18th Annual Meetings of the Federation of Cli$25,000
R13 · FY2018 · AI · contact PI
Stanford Technology Accelerating Medicines Partnership Center$2
UH2 · FY2018 · AR · contact PI
Large-Scale Characterization of Autoantibody Responses in Rheumatoid Arthritis$334,656
R01 · FY2017 · AR · contact PI
Large-Scale Sequencing and Characterizing of Autoantibody Responses$323,646
U19 · FY2017 · AI · contact PI
Genetic and Environmental Factors in the Response to Influenza Vaccination$320,554
U19 · FY2017 · AI · contact PI
Training Program in Adult and Pediatric Rheumatology$264,546
T32 · FY2017 · AR
FOCIS 2014 - 2018: The 14th through 18th Annual Meetings of the Federation of Cli$25,000
R13 · FY2017 · AI · contact PI
The Role of Coagulation and Fibrinolysis in Post-Traumatic Osteoarthritis$0
I01 · FY2017 · VA · contact PI
Investigating the Role of Fc Receptors in the Pathogenesis of Osteoarthritis$0
I01 · FY2017 · VA · contact PI
Large-Scale Sequencing and Characterizing of Autoantibody Responses$707,251
U19 · FY2016 · AI · contact PI
Large-Scale Characterization of Anti-Cancer Antibody Responses in Lung Adenocarci$399,643
R33 · FY2016 · CA · contact PI
Administrative Supplement - Stanford Technology Accelerating Medicines Partnership Center$366,240
UH2 · FY2016 · AR · contact PI
Large-Scale Characterization of Autoantibody Responses in Rheumatoid Arthritis$334,527
R01 · FY2016 · AR · contact PI
Training Program in Adult and Pediatric Rheumatology$264,901
T32 · FY2016 · AR
Genetic and Environmental Factors in the Response to Influenza Vaccination$251,055
U19 · FY2016 · AI · contact PI
Stanford Technology Accelerating Medicines Partnership Center$210,872
UH2 · FY2016 · AR · contact PI
FOCIS 2014 - 2018: The 14th through 18th Annual Meetings of the Federation of Cli$25,000
R13 · FY2016 · AI · contact PI
Investigating the Role of Fc Receptors in the Pathogenesis of Osteoarthritis$0
I01 · FY2016 · VA · contact PI
Stanford Technology Accelerating Medicines Partnership Center$1,250,001
UH2 · FY2015 · AR · contact PI
Large-Scale Characterization of Anti-Cancer Antibody Responses in Lung Adenocarci$399,643
R33 · FY2015 · CA · contact PI
Large-Scale Sequencing and Characterizing of Autoantibody Responses$359,080
U19 · FY2015 · AI · contact PI
Large-Scale Characterization of Autoantibody Responses in Rheumatoid Arthritis$334,468
R01 · FY2015 · AR · contact PI
Genetic and Environmental Factors in the Response to Influenza Vaccination$292,517
U19 · FY2015 · AI · contact PI
FOCIS 2014 - 2018: The 14th through 18th Annual Meetings of the Federation of Cli$25,000
R13 · FY2015 · AI · contact PI
Inflammatory Mechanisms in Traumatic Joint Injury and Repair$0
I01 · FY2015 · VA · contact PI
The Role of Coagulation and Fibrinolysis in Post-Traumatic Osteoarthritis$0
I01 · FY2015 · VA · contact PI
The Role of Coagulation and Fibrinolysis in Post-Traumatic Osteoarthritis$0
I01 · FY2015 · VA · contact PI
Investigating the Role of Fc Receptors in the Pathogenesis of Osteoarthritis$0
I01 · FY2015 · VA · contact PI
Inflammatory Mechanisms in Traumatic Joint Injury and Repair$0
I01 · FY2015 · VA · contact PI
The Role of Coagulation and Fibrinolysis in Post-Traumatic Osteoarthritis$0
I01 · FY2015 · VA · contact PI
Stanford Technology Accelerating Medicines Partnership Center$750,001
UH2 · FY2014 · AR · contact PI
Large-Scale Characterization of Anti-Cancer Antibody Responses in Lung Adenocarci$399,643
R33 · FY2014 · CA · contact PI
Large-Scale Sequencing and Characterizing of Autoantibody Responses$359,080
U19 · FY2014 · AI · contact PI
Large-Scale Characterization of Autoantibody Responses in Rheumatoid Arthritis$334,415
R01 · FY2014 · AR · contact PI
Genetic and Environmental Factors in the Response to Influenza Vaccination$268,514
U19 · FY2014 · AI · contact PI
FOCIS 2014 - 2018: The 14th through 18th Annual Meetings of the Federation of Cli$25,000
R13 · FY2014 · AI · contact PI
Investigating the Role of Fc Receptors in the Pathogenesis of Osteoarthritis$0
I01 · FY2014 · VA · contact PI
Inflammatory Mechanisms in Traumatic Joint Injury and Repair$0
I01 · FY2014 · VA · contact PI
The Role of Carboxypeptidase B and its Substrates in Rheumatoid Arthritis$375,366
R01 · FY2013 · AI · contact PI
Large-Scale Characterization of Autoantibody Responses in Rheumatoid Arthritis$334,365
R01 · FY2013 · AR · contact PI
The Role of Carboxypeptidase B and its Substrates in Rheumatoid Arthritis$399,229
R01 · FY2012 · AI · contact PI
Inflammatory Mechanisms in Traumatic Joint Injury and Repair$0
I01 · FY2012 · VA · contact PI
The Role of Carboxypeptidase B and its Substrates in Rheumatoid Arthritis$399,135
R01 · FY2011 · AI · contact PI
Tyrosine Kinase Pathways in Rheumatoid Arthritis$278,833
R01 · FY2011 · AR · contact PI
Proteomic Identification of Actionable Biomarkers in Rheumatoid Arthritis$500,000
RC1 · FY2010 · AR · contact PI
The Role of Carboxypeptidase B and its Substrates in Rheumatoid Arthritis$403,074
R01 · FY2010 · AI · contact PI
Tyrosine Kinase Pathways in Rheumatoid Arthritis$291,407
R01 · FY2010 · AR · contact PI
Proteomic Identification of Actionable Biomarkers in Rheumatoid Arthritis$500,000
RC1 · FY2009 · AR · contact PI
Tyrosine Kinase Pathways in Rheumatoid Arthritis$295,291
R01 · FY2009 · AR · contact PI
Tyrosine Kinase Pathways in Rheumatoid Arthritis$296,202
R01 · FY2008 · AR · contact PI
Anti-Fibrinogen Autoimmunity in Rheumatoid Arthritis$205,694
R21 · FY2008 · AI · contact PI
Tyrosine Kinase Pathways in Rheumatoid Arthritis$324,651
R01 · FY2007 · AR · contact PI
Anti-Fibrinogen Autoimmunity in Rheumatoid Arthritis$248,717
R21 · FY2007 · AI · contact PI
DNA VACCINE MEDIATED IMMUNOTHERAPY OF RHEUMATIC DISEASE$113,292
K08 · FY2004 · AR
DNA VACCINE MEDIATED IMMUNOTHERAPY OF RHEUMATIC DISEASE$113,292
K08 · FY2003 · AR
DNA VACCINE MEDIATED IMMUNOTHERAPY OF RHEUMATIC DISEASE$113,292
K08 · FY2002 · AR
DNA VACCINE MEDIATED IMMUNOTHERAPY OF RHEUMATIC DISEASE$113,292
K08 · FY2001 · AR
DNA VACCINE MEDIATED IMMUNOTHERAPY OF RHEUMATIC DISEASE$113,292
K08 · FY2000 · AR